Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Principal Investigator: Chatta, Gurkamal S

Respiratory Muscle Training During Breast Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity

Principal Investigator: O'Connor, Tracey L

Endobronchial Ultrasound Transbronchial Needle guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/II Study

Principal Investigator: Ivanick, Nathaniel M

(10505) A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Gliobastoma

Principal Investigator: Lipinski, Lindsay J

Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy

Principal Investigator: Wang, Eunice S

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Principal Investigator: Krishnamurthy, Anuradha

A Phase 1, multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitors in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Principal Investigator: Zsiros, Emese

Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors

Principal Investigator: Dy, Grace K

PROTOCOL RTOG 1216: RANDOMIZED PHASE II/III TRIAL OF ADJUVANT RADIATION THERAPY WITH CISPLATIN, DOCETAXEL-CETUXIMAB, OR CISPLATIN-ATEZOLIZUMAB IN PATHOLOGIC HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK (NCT 01810913)

Principal Investigator: Singh, Anurag K

(COG ANBL1821) A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Principal Investigator: Twist, Clare J

NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER

Principal Investigator: Fung-Kee-Fung, Simon

Phase I Study of the Safety of Intracavitary Photodynamic Therapy (PDT) of the Brain Bordering Resected Recurrent Glioblastoma or Gliosarcoma Using Intravenous Photobac® and a Balloon Light Applicator

Principal Investigator: Fenstermaker, Robert A

EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)

Principal Investigator: Singh, Anurag K

EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Principal Investigator: Singh, Anurag K

NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH
CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

Principal Investigator: Singh, Anurag K

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Cemiplimab in Patients with Advanced Cancers

Principal Investigator: Puzanov, Igor

Pilot Study of Episodic Future Thinking among Cigarette Smokers

Principal Investigator: Sheffer, Christine E

A Phase 1 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Chatta, Gurkamal S

(ASCT2031) A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or…

Principal Investigator: Twist, Clare J

A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

Principal Investigator: Frederick, Peter

(S1918) A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade…

Principal Investigator: Cortese, Matthew J

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

Principal Investigator: Wang, Eunice S

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer

Principal Investigator: Puzanov, Igor

An Open-Label Phase 1A/1B Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or with Azacitidine and Venetoclax for the Treatment of Subjects With Higher Risk Myelodysplastic Syndrome (MDS)…

Principal Investigator: Przespolewski, Amanda C

Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with…

Principal Investigator: Wang, Eunice S